Next Steps in Adoption of Maintenance Therapy with Immune Checkpoint Inhibitors
Drs. Gupta and Brown share their thoughts on the next steps that can aid in uptake of maintenance therapy in different tumor types.
Biomarkers and Clinical Endpoints to Guide Utilization of Maintenance Therapy
Two oncologists highlight practical considerations when choosing maintenance therapy.
Key Takeaways and Impact on Maintenance Therapy Use in Clinical Practice
Drs. Brown and Gupta discuss key takeaways from the study and the impact these data are likely to have on clinical practice.
Successes and Challenges with Maintenance Therapy
Shilpa Gupta, MD and Jason Brown, MD discuss trials with successful or negative results with maintenance therapy.
Presentation: Choosing Switch or Continuation Maintenance of Immune Checkpoint Inhibitors in Solid Tumors
Drs. Gupta and Brown review a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.